$TVRD Income Statement | Understand Stock

$TVRD

$0.87 +$0.02 (2.76%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Collaborative revenue
Commercial supply revenue
License and milestone fees
Royalty revenue
Clinical compound revenue
Other revenue
Total revenue
Cost of goods sold
Operating expenses:
Research and development
General and administrative
Restructuring
Total operating expenses
Loss from operations
Interest income
Other income (expense), net
Impairment of long-lived assets
Inventory write-down
Non-cash interest expense on liability related to sales of future royalties and milestones
Loss before benefit from income taxes
Benefit from income taxes
Net loss
Unrealized gain on short-term investments
Comprehensive loss
Net loss per share attributable to common stockholders, Basic (in dollars per share)
Net loss per share attributable to common stockholders, Diluted (in dollars per share)
Weighted-average common shares outstanding, Basic (in shares)
Weighted-average common shares outstanding, Diluted (in shares)
Change in unrealized gains (losses) on available-for-sale marketable securities

Comments